Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ANTI-INHIBITOR COAGULANT COMPLEX

Known as: coagulation factor IX, II, VII and X in combination, Factor VIII bypassing fraction, Factor VIII inhibitor bypassing activity 
A sterile, freeze dried fraction of human plasma containing factor VIII coagulant antigen and both the inactive and active forms of coagulation… Expand
National Institutes of Health

Related topics

Related topics

10 relations
ANTI-INHIBITOR COAGULANT COMPLEX 1 UNT InjectionDrug AllergyEnzyme Activators [MoA]Reversed Anticoagulation Activity [PE]
Expand

Narrower (2)

ANTI-INHIBITOR COAGULANT COMPLEX 1 UNT Injection [Feiba]Feiba

Broader (2)

Blood Coagulation FactorCoagulants

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Reversing Dabigatran in Life-Threatening Bleeding Occurring During Cardiac Ablation With Factor Eight Inhibitor Bypassing Activity
Objectives:We report a case of a patient receiving dabigatran who developed a life-threatening bleeding complication during… Expand
Is this relevant?
Highly Cited
2013
Highly Cited
2013
The use of FEIBA® in the correction of coagulation abnormalities induced by dabigatran
Studies have shown dabigatran to be an effective anticoagulant with an acceptable bleeding profile. None the less, these patients… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Edoxaban, an oral, direct factor Xa inhibitor, has a similar or low incidence of bleeding events compared with other… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
The development of inhibitory antibodies to factor VIII is a serious complication of hemophilia. FEIBA (factor VIII inhibitor… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision
Summary.  In haemophilia patients with inhibitor, elective orthopaedic surgery is usually performed under recombinant activated… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Treatment of acquired haemophilia with factor eight inhibitor bypassing activity
  • S. Sallah
  • Haemophilia : the official journal of the World…
  • 2004
    • Corpus ID: 816033
Summary.  Haemorrhagic manifestations in patients with acquired haemophilia can be fatal if not recognized and treated… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity.
  • L. Aledort
  • Journal of thrombosis and haemostasis : JTH
  • 2004
    • Corpus ID: 34862036
Thrombosis is a rare but well-recognized potential complication of Factor VIII Inhibitor Bypass Activity (FEIBA) infusion… Expand
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Factor VIII Inhibitor-Bypassing Agents Act by Inducing Thrombin Generation and Can Be Monitored by a Thrombin Generation Assay
Factor VIII (FVIII)-bypassing agents have complex modes of action but all control bleeding in inhibitor patients by triggering… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2001
Highly Cited
2001
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
UNLABELLED Melagatran is the active form of the oral, direct thrombin inhibitor H 376/95. In several animal models of thrombosis… Expand
Is this relevant?
Highly Cited
1997
Highly Cited
1997
Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity.
Factor VIII or factor IX replacement is frequently impossible in inhibitor-developing hemophiliacs, because of the level of the… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE